Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 6/20 | 0.33 |
| ▸ | CDK2 | P24941 | 6/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509982 | 0.81 | — | — | |
| SCHEMBL129817 | 0.81 | CHUK (0.44) | BRAFMAP3K5CDK1CDK2PDPK1 | |
| SCHEMBL8485064 | 0.79 | PDPK1 (0.36) | BRAFMAP3K5CDK1CDK2PDPK1 | |
| SCHEMBL20093433 | 0.77 | CDK2 (0.37) | BRAFMAP3K5CDK1CDK2PDPK1 | |
| SCHEMBL2938904 | 0.77 | BRAF (0.36) | BRAFCDK1CDK2PDPK1GDA | |
| SCHEMBL5699105 | 0.77 | HTT (0.36) | PDPK1 | |
| SCHEMBL9168808 | 0.77 | APP (0.44) | BRAFMAP3K5CDK1CDK2CCNB1 | |
| SCHEMBL8348019 | 0.77 | NLRP3 (0.40) | BRAFCDK1CDK2CCNB1CCNA2 | |
| Methylguanine SCHEMBL7217769 | 0.76 | BRAF (0.37) | BRAFMAP3K5CDK1CDK2CCNB1 | |
| Methylguanine SCHEMBL29968306 | 0.76 | CDK1 (0.41) | BRAFCDK1CDK2CCNB1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | claimed |
| EP-1171634-B1 | AMPLIFICATION AND SEQUENCING PRIMER PAIRS AND USE THEREOF | GEN PROBE INC (US) | 2005-10-26 | — | — | EP | claimed |
| US-20040049022-A1 | Composition & methods for treatment and screening | NYCE JONATHAN W (US) | 2004-03-11 | — | — | US | claimed |
| JP-2003517428-A | — | — | 2003-05-27 | — | — | JP | claimed |
| US-20030087845-A1 | COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION & TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION | EPIGENESIS PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | claimed |
| WO-2002085309-A2 | COMPOSITION, FORMULATIONS & KITS FOR TREATMENT OF RESPIRATORY & LUNG DISEASE WITH ANTI-SENSE OLIGONUCLEOTIDES & A BRONCHODILATING AGENT | EPIGENESIS PHARMACEUTICALS, INC. (US) | 2002-10-31 | — | — | WO | claimed |
| EP-1011608-A4 | COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF CARDIOPULMONARY AND RENAL FAILURE OR DAMAGE ASSOCIATED WITH ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR BROUGHT ABOUT BY ADMINISTRATION OF CERTAIN DRUGS | EPIGENESIS PHARMACEUTICALS INC (US) | 2002-05-15 | — | — | EP | claimed |
| US-6376183-B1 | HYBRIDIZING PRIMER TO TARGET AND EFFECTING CHAIN EXTENSION/CHAIN TERMINATION, USING PRIMER SELECTED FROM PRESYNTHESISED SET OF WALKING PRIMERS OF WHICH ANNEALING TEMPERATURES ARE RAISED AND/OR ANNEALING PROPERTIES IMPROVED | AMERSHAM PHARMACIA BIOTECH UK LIMITED (GB) | 2002-04-23 | — | — | US | claimed |
| EP-1019065-A4 | MULTIPLE TARGET HYBRIDIZING NUCLEIC ACIDS, THEIR PREPARATION, COMPOSITIONS, FORMULATION, KITS AND APPLICATIONS | UNIV EAST CAROLINA (US) | 2002-02-20 | — | — | EP | claimed |
| CN-1330513-A | Low adenosine antisense oligonucleotides, compositions, kits and methods for treating airway disorders associated with bronchoconstriction, pneumonia, allergy and surfactant deficiency | UNIV EAST CAROLINA (US) | 2002-01-09 | — | — | CN | claimed |
| EP-1019065-A1 | MULTIPLE TARGET HYBRIDIZING NUCLEIC ACIDS, THEIR PREPARATION, COMPOSITIONS, FORMULATION, KITS AND APPLICATIONS | EAST CAROLINA UNIVERSITY (US) | 2000-07-19 | — | — | EP | claimed |
| EP-1011608-A2 | COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF CARDIOPULMONARY AND RENAL FAILURE OR DAMAGE ASSOCIATED WITH ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR BROUGHT ABOUT BY ADMINISTRATION OF CERTAIN DRUGS | Epigenesis Pharmaceuticals, Inc. (US) | 2000-06-28 | — | — | EP | claimed |
| US-6074818-A | GENERATING PROFILES OF INCREASED FIDELITY USING OLIGONUCLEOTIDE PRIMERS WITH HAIRPIN STRUCTURES | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2000-06-13 | — | — | US | claimed |
| US-6043059-A | PERFORMING SERIES OF REACTIONS INVOLVING HYBRIDIZING PRIMER TO TARGET AND EFFECTING CHAIN EXTENSION/CHAIN TERMINATION; USING PRIMER FROM PRESYNTHESIZED SET HAVING RAISED ANNEALING TEMPERATURE AND/OR IMPROVED ANNEALING PROPERTIES | AMERSHAM PHARMACIA BIOTECH UK (GB) | 2000-03-28 | — | — | US | claimed |
| WO-1999063938-A9 | COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF CARDIOPULMONARY AND RENAL FAILURE OR DAMAGE ASSOCIATED WITH ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR BROUGHT ABOUT BY ADMINISTRATION OF CERTAIN DRUGS | EPIGENESIS PHARMACEUTICALS INC (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999063938-A2 | COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF CARDIOPULMONARY AND RENAL FAILURE OR DAMAGE ASSOCIATED WITH ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR BROUGHT ABOUT BY ADMINISTRATION OF CERTAIN DRUGS | EPIGENESIS PHARMACEUTICALS, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| US-5962221-A | Oligonucleotide constructs and methods for the generation of sequence signatures from nucleic acids | UNIVERSITY OF TENNESSEE RESEARCH CORPORATION, THE | 1999-10-05 | — | — | US | claimed |
| WO-1999013886-A1 | MULTIPLE TARGET HYBRIDIZING NUCLEIC ACIDS, THEIR PREPARATION, COMPOSITIONS, FORMULATION, KITS AND APPLICATIONS | EAST CAROLINA UNIVERSITY (US) | 1999-03-25 | — | — | WO | claimed |
| EP-0837950-A1 | PRIMER WALKING CYCLE SEQUENCING | Amersham Life Science (GB) | 1998-04-29 | — | — | EP | claimed |
| WO-1997001645-A1 | PRIMER WALKING CYCLE SEQUENCING | AMERSHAM LIFE SCIENCE (GB) | 1997-01-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087845-A1 | COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION & TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION | ADORA2B, ADORA2A, ADORA3 | BRAF 1470/4885MAP3K5 3668/4885CDK1 2436/4885 |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | BRAF 2862/4885MAP3K5 1506/4885CDK1 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.